Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.